“…As a result, a total of seventeen studies met the inclusion criteria and were identified as eligible studies (Figure 1). Totally, 7,813 cases and 9,602 controls were included from seventeen studies, including five studies for breast cancer with 3,099 cases and 3,697 controls (Yang et al, 2010;Zhang, 2011;Catucci et al, 2012;Zhang et al, 2012;Zhang et al, 2013), five for gastric cancer with 1,776 cases and 2,350 controls (Sun et al, 2010;Zhou et al, 2012;Xu et al, 2013b;Kupcinskas et al, 2014;Yang et al, 2014), two for colorectal cancer with 660 cases and 680 controls (Hezova et al, 2012;Zhang, 2012), and one for esophageal cancer (Wei et al, 2013), live cancer (Li, 2011), nasopharyngeal cancer (Li, 2011), renal cancer (Shi et al, 2012) or cervical cancer (Xiong et al, 2014). For ethnic distribution, in addition to four studies on Caucasian descent, including two for breast cancer (Yang et al, 2010;Catucci et al, 2012), one for gastric cancer (Kupcinskas et al, 2014) and one for colorectal cancer (Hezova et al, 2012), there were thirteen studies of Asian origin.…”